At the time of writing, Myriad Genetics, Inc [MYGN] stock is trading at $4.45, up 0.45%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MYGN shares have gain 8.27% over the last week, with a monthly amount drifted -39.86%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Myriad Genetics, Inc [NASDAQ: MYGN] stock has seen the most recent analyst activity on May 08, 2025, when Wolfe Research downgraded its rating to a Peer Perform. Previously, Wells Fargo downgraded its rating to Equal Weight on May 07, 2025, and kept the price target unchanged to $6. On April 09, 2025, downgrade downgraded it’s rating to Neutral. Piper Sandler upgraded its rating to a Overweight and increased its price target to $12.50 on March 12, 2025. Craig Hallum initiated its recommendation with a Buy and recommended $29 as its price target on February 12, 2025. UBS started tracking with a Neutral rating for this stock on December 10, 2024, and assigned it a price target of $18. In a note dated December 09, 2024, Leerink Partners downgraded an Market Perform rating on this stock and revised its target price from $30 to $21.
For the past year, the stock price of Myriad Genetics, Inc fluctuated between $3.81 and $29.30. Currently, Wall Street analysts expect the stock to reach $12.9 within the next 12 months. Myriad Genetics, Inc [NASDAQ: MYGN] shares were valued at $4.45 at the most recent close of the market. An investor can expect a potential return of 189.89% based on the average MYGN price forecast.
Analyzing the MYGN fundamentals
According to Myriad Genetics, Inc [NASDAQ:MYGN], the company’s sales were 831.30M for trailing twelve months, which represents an -3.12% plunge. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.14%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.15 and Total Capital is -0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Myriad Genetics, Inc [NASDAQ:MYGN] has a current ratio of 1.90. Further, the Quick Ratio stands at 1.71, while the Cash Ratio is 0.65. Considering the valuation of this stock, the price to sales ratio is 0.49, the price to book ratio is 0.58.
Transactions by insiders
Recent insider trading involved DIAZ PAUL J, President and CEO, that happened on Oct 11 ’24 when 15000.0 shares were sold. Officer, DIAZ PAUL J completed a deal on Oct 11 ’24 to buy 15000.0 shares. Meanwhile, Officer Ancona Margaret bought 11538.0 shares on Aug 21 ’24.
